{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:45:20Z","timestamp":1789764320631,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hardy of Oxford PharmaGenesis"},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda company"},{"name":"Children\u2019s National Medical Center"},{"name":"University Children\u2019s Hospital T\u00fcbingen"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgme.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T22:14:32Z","timestamp":1594851272000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1\/2 clinical trial"],"prefix":"10.1016","volume":"131","author":[{"given":"Christine","family":"\u00ed Dali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Kr\u00e4geloh-Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Wasilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.07.002_bb0005","series-title":"Scriver's Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Metachromatic leukodystrophy","author":"Gieselmann","year":"2018"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0010","series-title":"GeneReviews(R)","article-title":"Arylsulfatase A deficiency","author":"Gomez-Ospina","year":"2017"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1651-2227.2008.00648.x","article-title":"Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options","volume":"97","author":"Gieselmann","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy - an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic leukodystrophy: disease spectrum and approaches for treatment","volume":"29","author":"van Rappard","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0030","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1469-8749.2011.04028.x","article-title":"The natural course of gross motor deterioration in metachromatic leukodystrophy","volume":"53","author":"Kehrer","year":"2011","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1060-2","article-title":"Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers","volume":"14","author":"Harrington","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/NRL.0b013e3181b287c8","article-title":"Leukodystrophies: classification, diagnosis, and treatment","volume":"15","author":"Costello","year":"2009","journal-title":"Neurologist"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2017.08.006","article-title":"Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies","volume":"122","author":"Adang","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic Leukodystrophy compared with nontransplanted control patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0055","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2016-03-708479","article-title":"Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience","volume":"127","author":"van Rappard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0060","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0022-3476(06)80177-0","article-title":"Presymptomatic late-infantile metachromatic leukodystrophy treated with bone marrow transplantation","volume":"125","author":"Pridjian","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0065","first-page":"1003","article-title":"Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation","volume":"17","author":"Malm","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1705581","article-title":"Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression","volume":"39","author":"Bredius","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic stem cell gene therapy: Progress and lessons learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0085","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40259-015-0116-7","article-title":"Enzymes approved for human therapy: indications, mechanisms and adverse effects","volume":"29","author":"Baldo","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TACG.S86760","article-title":"Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa","volume":"9","author":"Su","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/14728214.2016.1123690","article-title":"Emerging drugs for the treatment of mucopolysaccharidoses","volume":"21","author":"Giugliani","year":"2016","journal-title":"Exp. Opin. Emerg Drugs"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0105","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/0192623311409595","article-title":"Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys","volume":"39","author":"Felice","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195186","article-title":"Nonclinical comparability studies of recombinant human arylsulfatase A addressing manufacturing process changes","volume":"13","author":"Wright","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase Alfa: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0145","series-title":"Gross Motor Function Measure (GMFM-66 and GMFM-88) User's Manual","author":"Russell","year":"2002"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0150","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1212\/WNL.0b013e3181feb217","article-title":"Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy","volume":"75","author":"Dali","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0155","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3174\/ajnr.A1739","article-title":"Metachromatic leukodystrophy: a scoring system for brain MR imaging observations","volume":"30","author":"Eichler","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0160","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/cpt.1752","article-title":"Pharmacokinetic Modeling of Intrathecally administered recombinant human Arylsulfatase a (TAK-611) in children with metachromatic Leukodystrophy","volume":"107","author":"Troy","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ar.1058","article-title":"Magnetic resonance spectroscopy of the human brain","volume":"265","author":"Ross","year":"2001","journal-title":"Anat. Rec."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF00869766","article-title":"Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo","volume":"241","author":"Kruse","year":"1993","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0175","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0180","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1177\/0883073816656401","article-title":"Metachromatic Leukodystrophy: an assessment of disease burden","volume":"31","author":"Eichler","year":"2016","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0185","first-page":"S396","article-title":"Intrathecal delivery of recombinant human arylsulfatase a in children with late-infantile metachromatic leukodystrophy: a post hoc analysis of responders and non-responders","volume":"84","author":"Giugliani","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2020.07.002_bb0190","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e31826e9ad2","article-title":"Cerebral gray and white matter changes and clinical course in metachromatic leukodystrophy","volume":"79","author":"Groeschel","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2020.07.002_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1113-6","article-title":"Phenotypic variation between siblings with metachromatic Leukodystrophy","volume":"14","author":"Elgun","year":"2019","journal-title":"Orphanet J Rare Dis"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:26:10Z","timestamp":1761089170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1096719220301529"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1\/2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}